{"id":3414,"date":"2021-01-25T11:25:57","date_gmt":"2021-01-25T19:25:57","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=3414"},"modified":"2021-01-26T11:27:00","modified_gmt":"2021-01-26T19:27:00","slug":"the-potential-public-health-and-economic-value-of-a-hypothetical-covid-19-vaccine-in-the-united-states-use-of-cost-effectiveness-modeling-to-inform-vaccination-prioritization","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/01\/25\/the-potential-public-health-and-economic-value-of-a-hypothetical-covid-19-vaccine-in-the-united-states-use-of-cost-effectiveness-modeling-to-inform-vaccination-prioritization\/","title":{"rendered":"The Potential Public Health and Economic Value of a Hypothetical COVID-19 Vaccine in the United States: Use of Cost-Effectiveness Modeling to Inform Vaccination Prioritization"},"content":{"rendered":"<p>A Markov cohort model estimating COVID-19 related direct medical costs and deaths in the US found that with a SARS-CoV-2 vaccine with 60% efficacy, the incremental cost per quality-adjusted life-year (QALY) gained for the US adult population would be $8,200 (compared to no vaccination). For those at high risk of hospitalization and death, vaccination was cost-saving compared to no vaccination, but the cost per QALY gained increased to over $94,000 for those at low risk. The study estimated that the vaccine could prevent 31% of expected deaths if large supplies were available, compared to 23% if supplies were limited.<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p><i>Kohli et al. (Jan 2021). The Potential Public Health and Economic Value of a Hypothetical COVID-19 Vaccine in the United States: Use of Cost-Effectiveness Modeling to Inform Vaccination Prioritization. Vaccine. <\/i><a href=\"https:\/\/doi.org\/10.1016\/j.vaccine.2020.12.078\">https:\/\/doi.org\/10.1016\/j.vaccine.2020.12.078<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A Markov cohort model estimating COVID-19 related direct medical costs and deaths in the US found that with a SARS-CoV-2 vaccine with 60% efficacy, the incremental cost per quality-adjusted life-year (QALY) gained for the US adult population would be $8,200 (compared to no vaccination). For those at high risk of hospitalization and death, vaccination was&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/01\/25\/the-potential-public-health-and-economic-value-of-a-hypothetical-covid-19-vaccine-in-the-united-states-use-of-cost-effectiveness-modeling-to-inform-vaccination-prioritization\/\">Read more<\/a><\/div>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[33],"topic":[31],"class_list":["post-3414","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-vaccines","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/3414","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=3414"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/3414\/revisions"}],"predecessor-version":[{"id":3415,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/3414\/revisions\/3415"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=3414"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=3414"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=3414"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=3414"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}